OKYO Pharma Limited(OKYO)Earnings, Financials & Key Ratios
OKYO•NASDAQ
Price updated Jun 19, 2026
AboutOKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.Show more
- Revenue$0
- EBITDA-$7M+54.2%
- Net Income-$5M+72.0%
- EPS (Diluted)-0.12-19900.0%
OKYO Key Insights
OKYO Pharma Limited (OKYO) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Profits declining 25.0% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Shares diluted 34.6% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when OKYO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
OKYO Price & Volume
OKYO Pharma Limited (OKYO) stock price & volume — 10-year historical chart
Loading chart...
OKYO Growth Metrics
OKYO Pharma Limited (OKYO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-26.38%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM47.56%
Return on Capital
10 Years-996.84%
5 Years-1077.89%
3 Years-2927.26%
Last Year-
OKYO Recent Earnings
OKYO Pharma Limited (OKYO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/12 qtrs (100%)
Q3 2026Latest
Jun 3, 2026Metric
Actual
Est
EPS
$0.04+49.8%
$0.08
Rev
—
—
Q1 2026
Jan 30, 2026Metric
Actual
Est
EPS
$0.01+85.7%
$0.07
Rev
—
—
Q1 2025
Jan 29, 2025Metric
Actual
Est
EPS
$0.08
—
Rev
—
—
Q2 2024
May 13, 2024Metric
Actual
Est
EPS
$0.30
—
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q3 2026Latest | Jun 3, 2026 | $0.04vs $0.08+49.8% | — |
| Q1 2026 | Jan 30, 2026 | $0.01vs $0.07+85.7% | — |
| Q1 2025 | Jan 29, 2025 | $0.08 | — |
| Q2 2024 | May 13, 2024 | $0.30 | — |
Based on last 12 quarters of dataView full earnings history →
OKYO Peer Comparison
OKYO Pharma Limited (OKYO) competitors in Ophthalmology Therapies and Delivery — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 LNTH | 6.76B | 103.86 | 30.46 | 0.5% | 18.05% | 24.33% | 0.00 | |
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 SGHT | 287.28M | 5.28 | -7.14 | -3.13% | -46.83% | -59.1% | 0.64 | |
 AVXL | 252.99M | 2.73 | -5.06 | -38.76% | ||||
 ALDX | 118.23M | 1.96 | -3.50 | -0% | 0.35 | |||
 HALO | 8.13B | 68.55 | 26.78 | 37.55% | 23.13% | 126.27% | 43.89 | |
 TARS | 2.72B | 63.16 | -39.72 | 146.71% | -9.02% | -14.19% | 0.27 | |
 PRPH | 355.28K | 0.08 | -0.04 | -35.82% | -339.31% | -157.67% | 2.46 |
Compare OKYO vs Peers
OKYO Pharma Limited (OKYO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
OKYO Income Statement
OKYO Pharma Limited (OKYO) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 0 | 0 | 219 | 5.97K | 13.09K | 2.42K | 3.8K | 3.87K | 2.56K | 6.82K |
COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
Gross Profit | 0▲ 0% | 0▲ 0% | -219▲ 0% | -5.97K▼ 2626.5% | -13.09K▼ 119.2% | -2.42K▲ 81.5% | -3.8K▼ 56.7% | -3.87K▼ 1.8% | -2.56K▲ 33.7% | -6.82K▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - | - | - |
Gross Profit Growth % | - | - | - | -2626.48% | -119.16% | 81.48% | -56.71% | -1.82% | 33.7% | - |
Operating Expenses | 363.27K | 985.82K | 4.54M | 1.51M | 3.37M | 6.22M | 6.34M | 15.69M | 7.19M | 9.98M |
OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
Selling, General & Admin | 363.2K | 573.43K | 1.85M | 995.42K | 2.97M | 4.93M | 6.75M | 7.45M | 4.93M | 7.77M |
SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
Research & Development | 0 | 0 | 3.04M | 517.46K | 348.35K | 1.61M | 6.34M | 8.24M | 2.25M | 2.21M |
R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | -12.43K | -15.81K | 0 | 43.65K | -320K | -6.75M | 0 | 0 | 0 |
Operating Income | -363K▲ 0% | -28.29M▼ 7692.3% | -4.54M▲ 84.0% | -1.52M▲ 66.5% | -4.13M▼ 172.1% | -6.23M▼ 50.7% | -13.09M▼ 110.0% | -15.69M▼ 19.9% | -7.19M▲ 54.2% | -9.99M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | - | - | - |
Operating Income Growth % | 67% | -7692.29% | 83.95% | 66.54% | -172.14% | -50.75% | -110.03% | -19.92% | 54.2% | - |
EBITDA | -310.48K | 76.32M | -4.54M | -1.51M | -4.12M | -6.23M | -13.08M | -15.69M | -7.19M | -6.98M |
EBITDA Margin % | - | - | - | - | - | - | - | - | - | - |
EBITDA Growth % | 72.25% | 24680.65% | -105.95% | 66.67% | -172.34% | -51.17% | -110.05% | -19.93% | 54.2% | -0.98% |
D&A (Non-Cash Add-back) | 52.52K | 104.61M | 218 | 5.97K | 13.11K | 2.33K | 3.8K | 3.87K | 2.56K | 3.45K |
EBIT | -365K | 0 | -4.53M | -1.5M | -3.37M | -6.22M | -13.19M | -15.75M | -7.09M | -9.6M |
Net Interest Income | 0 | 0 | 0 | 46.91K | -1.12K | 0 | -96.69K | -1.05M | -878.17K | -963.81K |
Interest Income | 4.42K | 0 | 0 | 48.06K | 0 | 0 | 0 | 0 | 5.47K | 5.47K |
Interest Expense | 0 | 0 | 0 | 1.16K | 1.12K | 0 | 96.69K | 1.05M | 883.65K | 969.28K |
Other Income/Expense | 121.34K | -12.44K | -363K | -99.49K | 754.85K | 0 | -196.62K | -1.11M | -781.2K | -575.56K |
Pretax Income | -242K▲ 0% | -28.27M▼ 11580.6% | -4.9M▲ 82.7% | -1.62M▲ 67.0% | -3.38M▼ 108.8% | -6.22M▼ 84.0% | -13.28M▼ 113.6% | -16.8M▼ 26.5% | -7.97M▲ 52.6% | -10.56M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | - | - | - |
Income Tax | 0 | 0 | 0 | -76.19K | -24.99K | -787K | -12.2K | 22.41K | -3.26M | -3.26M |
Effective Tax Rate % | 0% | 0% | 0% | 4.71% | 0.74% | 12.66% | 0.09% | -0.13% | 40.95% | 30.89% |
Net Income | -243K▲ 0% | -28.3M▼ 11545.7% | -4.89M▲ 82.7% | -1.54M▲ 68.5% | -3.35M▼ 117.5% | -5.43M▼ 61.9% | -13.27M▼ 144.4% | -16.83M▼ 26.8% | -4.71M▲ 72.0% | -7.3M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | - | - | - |
Net Income Growth % | 70.37% | -11545.68% | 82.7% | 68.5% | -117.49% | -61.93% | -144.37% | -26.77% | 72.03% | -26.38% |
Net Income (Continuing) | -242K | -28.27M | -4.9M | -1.54M | -3.35M | -5.43M | -13.27M | -16.83M | -4.71M | -7.3M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.04▲ 0% | -4.80▼ 11522.3% | -0.62▲ 87.1% | -0.17▲ 72.6% | -0.32▼ 88.2% | -0.36▼ 12.5% | -0.60▼ 66.7% | -0.00▲ 99.9% | -0.12▼ 19900.0% | -0.20▲ 0% |
EPS Growth % | 70.5% | -11522.28% | 87.08% | 72.58% | -88.24% | -12.5% | -66.67% | 99.9% | - | 47.56% |
EPS (Basic) | -0.04 | -4.80 | -0.62 | -0.17 | -0.32 | -0.36 | -0.60 | -0.00 | -0.12 | - |
Diluted Shares Outstanding | 5.86M | 5.89M | 7.91M | 9.16M | 10.35M | 15.06M | 22.26M | 29.34M | 39.49M | 37.42M |
Basic Shares Outstanding | 5.86M | 5.89M | 7.91M | 9.16M | 10.35M | 15.06M | 22.26M | 29.34M | 39.49M | 37.42M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
OKYO Balance Sheet
OKYO Pharma Limited (OKYO) balance sheet — assets, liabilities & shareholders' equity
| Metric | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 16.86M | 48 | 758.75K | 566.73K | 6.99M | 4.3M | 5.2M | 1.54M | 3.68M | 4.64M |
Cash & Short-Term Investments | 16.86M | 0 | 627.56K | 234.96K | 6.89M | 2.7M | 4.05M | 826.85K | 1.56M | 4.22M |
Cash Only | 0 | 0 | 627.56K | 234.96K | 6.89M | 2.7M | 4.05M | 826.85K | 1.56M | 4.22M |
Short-Term Investments | 16.86M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 48 | 111.36K | 326.22K | 4.5K | 883.43K | 980.08K | 580.94K | 1.89M | 23.41K |
Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 126 | -792 | 34 | -1.49K | 170.31K | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | 209.68 | - | 0.95 | - | 16.37K | - | - | - |
Other Current Assets | 0 | 0 | 85.46K | 15 | 71.75K | 1.49K | -170.31K | 0 | 0 | 4.5K |
Total Non-Current Assets | 0 | 0 | 1.1K | 30.66K | 104.64K | 5.22K | 7.22K | 3.35K | 2.04K | 1.18K |
Property, Plant & Equipment | 0 | 0 | 1.1K | 30.66K | 104.64K | 5.22K | 7.22K | 3.35K | 2.04K | 1.18K |
Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Assets | 0▲ 0% | 0▲ 0% | 759.86K▲ 0% | 597.4K▼ 21.4% | 7.09M▲ 1087.0% | 4.3M▼ 39.4% | 5.2M▲ 21.0% | 1.54M▼ 70.4% | 3.68M▲ 138.6% | 4.64M▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
Asset Growth % | -100% | - | - | -21.38% | 1087.03% | -39.35% | 21% | -70.38% | 138.59% | 132.37% |
Total Current Liabilities | 0 | 0 | 426.72K | 710.66K | 1.71M | 1.35M | 7.26M | 7.42M | 9.23M | 8.06M |
Accounts Payable | 141.79K | 0 | 381.76K | 593.72K | 210.99K | 517.67K | 1.02M | 6.13M | 7.9M | 0 |
Days Payables Outstanding | - | - | 635.78K | 36.29K | 5.89K | 77.98K | 98.42K | 578.57K | 1000K | 316.33K |
Short-Term Debt | 0 | 0 | 0 | 0 | 34.14K | 0 | 2.22M | 0 | 0 | 185.79K |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 87.59K | -1.13K | -26.73K | 1.43M | 323.06K | 1.29M | 0 | 0 | 7.72M |
Current Ratio | - | - | 1.78x | 0.80x | 4.09x | 3.17x | 0.72x | 0.21x | 0.40x | 0.58x |
Quick Ratio | - | - | 1.78x | 0.80x | 4.09x | 3.18x | 0.69x | 0.21x | 0.40x | 0.58x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 0 | 0 | 0 | 26.54K | 64.61K | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 21.45K | 64.61K | 0 | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 5.08K | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 0 | 0 | 426.72K | 737.2K | 1.77M | 1.35M | 7.26M | 7.42M | 9.23M | 8.06M |
Total Debt | 0 | 0 | 0 | 25.56K | 98.76K | 0 | 2.22M | 0 | 0 | 185.79K |
Net Debt | 0 | 0 | -627.56K | -209.4K | -6.79M | -2.7M | -1.83M | -826.85K | -1.56M | -4.03M |
Debt / Equity | - | - | - | - | 0.02x | - | - | - | - | -0.05x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.03x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.58x |
Interest Coverage | - | - | - | -1298.12x | -2997.33x | - | -136.39x | -14.95x | -8.02x | -9.90x |
Total Equity | 0▲ 0% | 0▲ 0% | 333.14K▲ 0% | -139.8K▼ 142.0% | 5.32M▲ 3905.0% | 2.95M▼ 44.6% | -2.05M▼ 169.7% | -5.88M▼ 186.4% | -5.55M▲ 5.6% | -3.42M▲ 0% |
Equity Growth % | -100% | - | - | -141.96% | 3905.04% | -44.59% | -169.66% | -186.36% | 5.61% | -379.92% |
Book Value per Share | - | - | 0.04 | -0.02 | 0.51 | 0.20 | -0.09 | -0.20 | -0.14 | -0.09 |
Total Shareholders' Equity | 0 | 0 | 333.14K | -139.8K | 5.32M | 2.95M | -2.05M | -5.88M | -5.55M | -3.42M |
Common Stock | 0 | 0 | 89.22M | 0 | 0 | 123.98M | 0 | 143.11M | 0 | 0 |
Retained Earnings | 0 | 0 | -88.97M | -85.88M | -99.4M | -112.43M | -125.7M | -142.52M | -143.02M | -145.61M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 82.12K | 2.22M | 12.82M | -11.01M | -7.74M | -11.31M | -11.47M | -9.03M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
OKYO Cash Flow Statement
OKYO Pharma Limited (OKYO) cash flow — operating, investing & free cash flow history
| Metric | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -651.27K | -1.59M | -1.99M | -1.2M | -1.6M | -5.47M | -7.7M | -9.49M | -1.81M | -6.04M |
Operating CF Margin % | - | - | - | - | - | - | - | - | - | - |
Operating CF Growth % | -0.06% | -144.89% | -24.77% | 39.59% | -33.12% | -241.71% | -40.73% | -23.33% | 80.92% | -359.04% |
Net Income | -241.93K | -28.27M | -4.9M | -1.62M | -3.38M | -6.22M | -13.28M | -16.83M | -7.97M | -7.3M |
Depreciation & Amortization | 0 | 0 | 218 | 5.98K | 13.11K | 2.33K | 3.8K | 3.87K | 2.56K | 3.45K |
Stock-Based Compensation | 18.37K | 4.24K | 50.53K | 36.34K | 544.39K | 1.72M | 1.27M | 1.12M | 734.99K | 4M |
Deferred Taxes | 0 | 0 | -1.17K | 146.58K | 92.95K | -9.41K | 250.34K | 0 | 0 | 0 |
Other Non-Cash Items | 0 | 26.63M | 2.69M | 42.84K | 83K | 61.72K | -84.16K | 3.54M | 1.8M | 1.29M |
Working Capital Changes | -427.71K | 35.72K | 176.81K | 186.53K | 1.04M | -1.02M | 4.14M | 2.67M | 3.63M | 1.3M |
Change in Receivables | 0 | 0 | 0 | -543 | 205.07K | 27.38K | 167.72K | 440.26K | -90.4K | -462.05K |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 0 | 0 | 0 | 0 | 0 | -297.99K | 0 | 2.8M | 0 | 0 |
Cash from Investing | -375.39K | 0 | -1.32K | -132.67K | -18.11K | -1.67K | -5.92K | 0 | -1.21K | -1.21K |
Capital Expenditures | -375.39K | 0 | -1.32K | 0 | -6.94K | -1.67K | -5.92K | 0 | -1.21K | -1.21K |
CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -373.6K | 0 | 0 | -132.67K | -21 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 4.42K | 0 | 0 | 963.31K | 7.83M | 2.15M | 9.32M | 6.21M | 2.66M | 9.18M |
Debt Issued (Net) | 4.42K | 0 | 0 | 0 | 7.58M | 0 | 2M | 0 | 950K | 950K |
Equity Issued (Net) | 0 | 0 | 0 | 0 | 230.02K | 1.43M | 7.32M | 6.21M | 1.71M | 6.02M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 0 | 0 | 963.31K | 15.87K | 725.51K | 0 | 0 | 0 | 2.21M |
Net Change in Cash | -651.27K▲ 0% | -1.59M▼ 144.9% | -1.99M▼ 24.9% | -392.13K▲ 80.3% | 6.65M▲ 1796.8% | -4.19M▼ 163.0% | 1.34M▲ 132.1% | -3.22M▼ 339.4% | 734.05K▲ 122.8% | 1.9M▲ 0% |
Free Cash Flow | -1.03M▲ 0% | -1.59M▼ 55.3% | -1.99M▼ 24.9% | -1.2M▲ 39.6% | -1.61M▼ 33.7% | -5.47M▼ 240.3% | -7.7M▼ 40.8% | -9.49M▼ 23.2% | -1.81M▲ 80.9% | -6.04M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | - | - | - |
FCF Growth % | 2.86% | -55.35% | -24.85% | 39.63% | -33.7% | -240.34% | -40.8% | -23.24% | 80.91% | 62.8% |
FCF per Share | -0.18 | -0.27 | -0.25 | -0.13 | -0.16 | -0.36 | -0.35 | -0.32 | -0.05 | -0.16 |
FCF Conversion (FCF/Net Income) | 2.68x | 0.06x | 0.41x | 0.78x | 0.48x | 1.01x | 0.58x | 0.56x | 0.38x | 0.83x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
OKYO Key Ratios
OKYO Pharma Limited (OKYO) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | - | -1469.36% | -1595.28% | -129.51% | -131.39% | -2968.58% | - | - | 132.33% |
Return on Invested Capital (ROIC) | - | - | -17587.12% | - | - | -1894.47% | - | - | - | 101.66% |
Debt / Equity | - | - | - | - | 0.02x | - | - | - | - | -0.05x |
Interest Coverage | - | - | - | -1298.12x | -2997.33x | - | -136.39x | -14.95x | -8.02x | -9.90x |
FCF Conversion | 2.68x | 0.06x | 0.41x | 0.78x | 0.48x | 1.01x | 0.58x | 0.56x | 0.38x | 0.83x |
Related:OKYO Dividend History·OKYO Revenue History·OKYO Price History·OKYO P/E History·OKYO Financial Ratios·OKYO Institutional Holders
OKYO Frequently Asked Questions
OKYO Pharma Limited (OKYO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
OKYO Pharma Limited (OKYO) grew revenue by 0.0% over the past year. Growth has been modest.
OKYO Pharma Limited (OKYO) reported a net loss of $7.3M for fiscal year 2025.
Dividend & Returns
OKYO Pharma Limited (OKYO) had negative free cash flow of $6.0M in fiscal year 2025, likely due to heavy capital investments.